Biologics - beyond the joints

Z. Szekanecz, S. Szántó, Z. Szabó, Andrea Váncsa, Szilvia Szamosi, Nóra Bodnár, G. Szűcs

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.

Original languageEnglish
Pages (from-to)820-824
Number of pages5
JournalAutoimmunity Reviews
Volume9
Issue number12
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Biological Products
Joints
Arthritis
Interleukin-6 Receptors
Bone Diseases
Uveitis
Inflammatory Bowel Diseases
Psoriasis
Observational Studies
B-Lymphocytes
Cardiovascular Diseases
Tumor Necrosis Factor-alpha
T-Lymphocytes
Therapeutics

Keywords

  • Ankylosing spondylitis
  • Atherosclerosis
  • Biologics
  • Cardiovascular disease
  • Inflammatory bowel disease
  • Psoriasis
  • Rheumatoid arthritis
  • Uveitis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Biologics - beyond the joints. / Szekanecz, Z.; Szántó, S.; Szabó, Z.; Váncsa, Andrea; Szamosi, Szilvia; Bodnár, Nóra; Szűcs, G.

In: Autoimmunity Reviews, Vol. 9, No. 12, 10.2010, p. 820-824.

Research output: Contribution to journalArticle

Szekanecz, Z. ; Szántó, S. ; Szabó, Z. ; Váncsa, Andrea ; Szamosi, Szilvia ; Bodnár, Nóra ; Szűcs, G. / Biologics - beyond the joints. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 12. pp. 820-824.
@article{b348a69d7395462888cef8693a19e03d,
title = "Biologics - beyond the joints",
abstract = "Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.",
keywords = "Ankylosing spondylitis, Atherosclerosis, Biologics, Cardiovascular disease, Inflammatory bowel disease, Psoriasis, Rheumatoid arthritis, Uveitis",
author = "Z. Szekanecz and S. Sz{\'a}nt{\'o} and Z. Szab{\'o} and Andrea V{\'a}ncsa and Szilvia Szamosi and N{\'o}ra Bodn{\'a}r and G. Szűcs",
year = "2010",
month = "10",
doi = "10.1016/j.autrev.2010.07.011",
language = "English",
volume = "9",
pages = "820--824",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Biologics - beyond the joints

AU - Szekanecz, Z.

AU - Szántó, S.

AU - Szabó, Z.

AU - Váncsa, Andrea

AU - Szamosi, Szilvia

AU - Bodnár, Nóra

AU - Szűcs, G.

PY - 2010/10

Y1 - 2010/10

N2 - Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.

AB - Biologics including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.

KW - Ankylosing spondylitis

KW - Atherosclerosis

KW - Biologics

KW - Cardiovascular disease

KW - Inflammatory bowel disease

KW - Psoriasis

KW - Rheumatoid arthritis

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=77956908650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956908650&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.07.011

DO - 10.1016/j.autrev.2010.07.011

M3 - Article

C2 - 20667515

AN - SCOPUS:77956908650

VL - 9

SP - 820

EP - 824

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 12

ER -